Madrigal Pharmaceuticals, Inc. (MDGL) Stock Price & Analysis
Madrigal Pharmaceuticals, Inc. (MDGL) rose 0.21% to USD 544.51 as of July 25, 2026 at 03:07 UTC, according to Nexqual real-time market data.
MDGL last closed at USD 543.35; the session ranged USD 537–547.91 on volume of 147,388 shares. Market capitalization is $12.55B, with a 52-week range of USD 286.44–615 (NMS). Source: Nexqual, July 25, 2026 at 03:07 UTC.
Key Statistics (as of July 25, 2026 at 03:07 UTC)
| Price | USD 544.51 |
|---|---|
| Change | ▲ 0.21% (up) |
| Previous Close | USD 543.35 |
| Open | USD 544.37 |
| Day Range | USD 537 – 547.91 |
| 52-Week Range | USD 286.44 – 615 |
| Volume | 147,388 shares |
| Market Cap | $12.55B |
| Exchange | NMS |
Technical Analysis (MDGL)
Nexqual's technical model rates MDGL "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 03:07 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 56.6 (neutral) |
| vs SMA50 | Above (USD 516.73) |
| MACD | 8.56 (positive) |
Analyst Ratings (MDGL)
Wall Street analysts rate MDGL "Strong Buy" based on 14 analysts, with a mean price target of USD 679.64 (range USD 553–964), per Nexqual as of July 25, 2026 at 03:07 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 679.64 |
| High Target | USD 964 |
| Low Target | USD 553 |
| Buy / Hold / Sell | 14 / 2 / 0 |
Earnings (MDGL)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD -2.23 |
| Revenue Estimate | $352.11M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.38 vs est -4.14 ▲ beat |
| 2025-12-31 | USD -2.57 vs est -0.88 ▼ miss |
| 2025-09-30 | USD -4.96 vs est -1.99 ▼ miss |
| 2025-06-30 | USD -1.9 vs est -3.53 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:07 UTC.
Financials & Fundamentals (MDGL)
| Total Revenue | $1.13B |
|---|---|
| Revenue Growth (YoY) | +126.80% |
| Gross Margin | +93.07% |
| Operating Margin | -29.78% |
| Profit Margin | -27.32% |
| ROE | -49.35% |
| Debt / Equity | 63.91 |
| Current Ratio | 3.5 |
| Total Cash | $812.77M |
| Total Debt | $347.31M |
| Free Cash Flow | $-156.40M |
Source: Nexqual, July 25, 2026 at 03:07 UTC.
Financial Health Score (MDGL)
Nexqual rates Madrigal Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:07 UTC.
| Growth | Strong — Revenue +432% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 93%, operating -30% |
| Balance Sheet | Strong — $813M cash vs $347M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$156M, burning cash |
| Efficiency | Critical — ROE -49%, ROA -17.6% |
Ownership (MDGL)
| Insider Ownership | +5.89% |
|---|---|
| Institutional Ownership | +107.08% |
| Shares Outstanding | 23.06M |
| Float | 13.85M |
| Short % of Float | +17.99% |
Source: Nexqual, July 25, 2026 at 03:07 UTC.
Leadership (MDGL)
Madrigal Pharmaceuticals, Inc. is led by William J. Sibold (age 59), CEO, President & Director, per Nexqual as of July 25, 2026 at 03:07 UTC.
| CEO, President & Director | William J. Sibold (age 59) |
|---|---|
| Founder, Senior Scientific & Medical Advisor and Director | Rebecca A. Taub (age 73) |
| Executive VP & CFO | Mardi C. Dier (age 61) |
| Executive Vice President of Business Planning & Operations | Mark Underwood |
Major Backers & Investors (MDGL)
Notable institutional backers of Madrigal Pharmaceuticals, Inc. include Baker Bros. Advisors, LP, Janus Henderson Group PLC, RTW Investments LP, according to Nexqual as of July 25, 2026 at 03:07 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Baker Bros. Advisors, LP | 9.29% |
| Janus Henderson Group PLC | 8.76% |
| RTW Investments LP | 8.65% |
| Avoro Capital Advisors LLC | 7.89% |
| PAULSON & CO. INC. | 6.04% |
| JANUS INVESTMENT FUND-Janus Henderson Forty Fund | 3.69% |
| Wellington Management | 3.01% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 15.32% |
| BlackRock | 8.54% |
| State Street | 3.55% |
Source: Nexqual, July 25, 2026 at 03:07 UTC.
From Madrigal Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- As our international operations grow, we will continue to reassess our approach to manage our risk relating to fluctuations in currency rates.
Partnerships
- In December 2025, we entered into an exclusive global license agreement with Pfizer (the "Pfizer License Agreement") to develop, manufacture and commercialize ervogastat, a Phase 2 oral DGAT-2 inhibitor, and two additional early-stage MASH assets.
- Blue Owl Credit Facility On July 17, 2025 (the "Closing Date"), we entered into the Financing Agreement with the Lenders and the Administrative Agent.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VKTX | Viking Therapeutics, Inc. | USD 34.79 | ▼ 6.75% |
| AXSM | Axsome Therapeutics, Inc. | USD 241 | ▲ 0.58% |
| BBIO | BridgeBio Pharma, Inc. | USD 84.02 | ▲ 1.65% |
| KRYS | Krystal Biotech, Inc. | USD 335.19 | ▼ 0.48% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 102.1 | ▼ 1.8% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:07 UTC. This page is informational and not investment advice.